Federal Circuit: Reverses Motion to Dismiss—Generic Manufacturer’s Label Combined with its Expansive Public Statements Plausibly Induced Infringement

June 25, 2024

Reading Time : 2 min

The Federal Circuit reversed a decision from the District of Delaware dismissing a case for failing to plead induced infringement because the totality of the evidence raised fact questions that could not be resolved on a motion to dismiss. The Federal Circuit expressed doubts about whether appellee’s FDA-approved label alone, which carved out the claimed indication, was sufficient to actively induce. But the court held appellee’s label combined with its public statements that broadly refer to its drug as a generic version and provide usage and sales data for carved out indications, created a plausible basis for pleading induced infringement.

This appeal stems from an infringement suit brought in the District of Delaware for infringement of claims for reducing cardiovascular events brought against a generic manufacturer of appellant’s drug, Vascepa. In 2012, Vascepa was approved for the treatment of severe hypertriglyceridemia (SH). When Vascepa was first approved, its label included an express “limitation of use,” stating its effect on cardiovascular mortality and morbidity was not yet determined. In 2019, the FDA approved Vascepa to reduce cardiovascular risk. As a result of this approval, the limitation of use was removed from the Vascepa label. 

Appellee in this case sought a label for the SH indication, and initially included the limitation of use language in its label. After Vascepa was approved to reduce cardiovascular risk, appellee revised its ANDA to indicate that it was seeking a “skinny label” for only the SH indication and would carve out the cardiovascular risk indication. Appellee also removed the limitation of use language from its proposed label.  Around the time appellee received approval for its generic Vascepa, it issued several press releases touting its drug as generic Vascepa without limitation and citing to overall U.S. sales of Vascepa, including sales attributable to the cardiovascular risk indication. Appellee also established a website that included, in small letters, the statement that its generic was approved for fewer than all approved indications for Vascepa.

The district court dismissed appellants complaint for infringement for failing to adequately plead inducement, and more specifically for failing to adequately allege acts that constitute active inducement of the asserted patents. According to the district court, the warnings of side effects in appellee’s label did not recommend, encourage or promote infringement. Likewise, the press releases, while potentially evidence of intent, did not plausibly evidence an inducing act

On appeal, the Federal Circuit disagreed. The Federal Circuit took issue with the district court’s evaluation of the allegations, holding that on a motion to dismiss where the generic product is already approved (i.e., not your typical Hatch-Waxman case), the evidence must be viewed in its totality, not piecemeal as the district court had done. The Federal Circuit explained that this was not a typical “skinny label” case where the allegations are based solely on the label. Instead, the evidence here encompassed the combination of the label, public statements, and marketing materials, including public statements that provide usage information and sales data about the cardiovascular risk indication. Here, the appellee did not merely market its drug as a generic or merely skinny label around an indication, it did much more. Thus, based on the totality of the material cited in the complaint, the Federal Circuit held it is plausible that a physician could discern an encouragement to use the generic Vascepa for indications other than SH. 

Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., Case No. 2023-1169 (Fed. Cir. Jun. 25, 2023)

Share This Insight

Previous Entries

IP Newsflash

November 1, 2024

The Federal Circuit’s decision in Kyocera Senco Industrial Tools Inc. v. International Trade Commission articulated a bright-line test for patent expert admissibility: to testify from the perspective of a “person of ordinary skill in the art” (POSITA), the expert must at least meet the definition of a POSITA for the patents-in-suit. Absent that level of skill, Kyocera holds that the witness’s testimony is not sufficiently reliable or relevant enough to be relied on by a fact-finder.

...

Read More

IP Newsflash

October 29, 2024

The PTAB denied a petitioner’s motion to compel routine discovery that sought information from a parallel ITC investigation for alleged inconsistent positions taken by patent owner in the IPR. The board found that patent owner had not taken inconsistent positions but warned patent owner that it had an ongoing duty to produce any information inconsistent with arguments made during the present IPR, even if that information related to arguments patent owner had dropped at the ITC.

...

Read More

IP Newsflash

October 11, 2024

The Central District of California ruled that the heightened pleading standard of Federal Rule of Civil Procedure 9(b) applies to all three prongs of a false patent marking claim, including the third prong, competitive injury. In doing so, took a clear stand on an issue with a nationwide split among district courts.

...

Read More

IP Newsflash

October 3, 2024

The Federal Circuit recently upheld the USPTO’s authority under the estoppel provision 37 C.F.R. § 42.73(d)(3)(i) to prohibit a patent owner from obtaining patent claims that are not patentably distinct from claims previously declared unpatentable in inter partes review (IPR) proceedings. However, the court clarified that the regulation applies only to new claims or amended claims, not previously issued claims.

...

Read More

IP Newsflash

September 27, 2024

In Kyocera Senco Industrial Tools Inc. v. International Trade Commission, the Federal Circuit held that an expert must meet the definition of a “person of ordinary skill in the art” of the asserted patents in order to opine on infringement, among other issues. This new bright-line test and the underlying rationale, however, raised several new questions regarding expert admissibility. SeeFederal Circuit: Narrow Definition of Skill in the Art Dooms Expert’s Testimony” and “Grappling With A Bright-Line Patent Expert Admissibility Test.” The Federal Circuit recently addressed one of those questions, namely whether an expert must have acquired the requisite level of skill as of the time of the invention or whether it is sufficient for an expert to acquire that knowledge at a later date.

...

Read More

IP Newsflash

September 23, 2024

The Director of the USPTO initiated sua sponte review of a PTAB panel’s decision to impose sanctions based on patentee’s conduct during IPR proceedings. The PTAB cancelled all of patentee’s claims, including those not unpatentable on the merits, after finding that patentee deliberately withheld data relevant to the patentability of the claims at issue. In her review, the Director addressed which regulations are implicated upon a party’s misconduct during AIA proceedings and addressed whether entry of judgment in the trial was an appropriate sanction.

...

Read More

IP Newsflash

September 18, 2024

The Western District of Texas granted a motion to stay a patent infringement lawsuit pending inter partes review not only because doing so would simplify the issues in the still-early litigation and reduce the burden on the parties, but also because the non-moving party failed to diligently file its lawsuit despite a protracted negotiations period.

...

Read More

IP Newsflash

September 16, 2024

The Federal Circuit dismissed an appeal from an inter partes review (“IPR”) final written decision for lack of standing where it found the appellant failed to provide evidence sufficient to show it suffered an injury in fact.

...

Read More

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.